1. Scrip
  2. >>Business

Scrip’s Rough Guide To Targeted Protein Degradation

Drugging The Undruggable

 
• By Alexandra Shimmings

By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. Scrip takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.  

Ubiquitinin
Ligase enzyme tags protein for degradation by attaching a ubiquitin molecule • Source: Alamy

Targeted protein degradation, or TPD, has been steadily gaining attention in recent years as a highly promising new drug development strategy that has already attracted significant investment and big pharma attention.

With observers eagerly awaiting early clinical data for a range of novel TPD candidates, Scrip explains how these products work,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.